以追求身心完美為名：生活機能醫藥對健康照護的危害

In the Name of Pursuing Betterness: The Potential Menance of Lifestyle Medicines to Health

10.6288/TJPH2007-26-06-01

丁志音(Chih-Yin Lew-Ting)；劉芳助(Fang-Zhu Liu)；李袖瑜(Hsiu-Yu Li)

生活機能醫藥 ； 健康強化科技 ； 健康照護牟利化 ； 醫療化 ； Lifestyle medicines ； health enhancement technology ； profitalization of health care ； medicalization

台灣公共衛生雜誌

26卷6期（2007 / 12 / 01）

443 - 451

繁體中文

2自1998年繼sildenafil（Viagra威而剛）及其後fluoxetine（Prozac百憂解）的問世及使用的急速狂升後，類似的藥物便廣泛被應用於諸多生活方式問題的介入，以便修飾、提升身心的狀態，來強化外觀的、認知及心理的、社會的特殊功能的表現，試圖達到特定或整體的完美與快樂。本文以生活機能醫藥為例，來探討健康強化科技的興起對醫療照護體系甚至人類生活所帶來的衝擊。除了提出生活機能醫藥的定義與範疇外，本文主要由三個層面來探討生活機能醫藥對健康照護體系與人類健康的長遠影響：操弄需求與創造市場、對醫療照護的衝擊與挑戰、以及超越醫療照護的人類本質改變。綜合言之，健康強化科技如生活方式醫藥者，涉及龐大的商業利益，可使健康照護體系與醫學專業產生徹底的質變。除了危及病人安全與真正疾病治療的品質之外，將邁向無止境的人體甚至情緒與心性改造，其終極作用，難於估量。政策制訂者及學術界宜開始關切相關科技產品的使用趨勢與可能影響，並應著手發展管制措施。

Since 1998 when sildenafil (Viagra) and fluoxetine (Prozac) were first presented and subsequently increased rapidly in use, lifestyle drugs as such have been widely used to tackle various lifestyle problems, aiming to modify and enhance the state of mind and body. This article takes the lifestyle medicines as an example to elucidates how health enhancement technologies may influence health care system and human health. In addition to exploring the definition and scope of lifestyle medicines, the article examines the following three aspects pertaining to the issue: needs manipulation and the creation of markets, impacts on health care system, and, beyond health care, the alteration of human essence. In sum, Health enhancement technology such as lifestyle medicines could change the imperatives of health care system and the nature of medicine, not only endangering patient safety and quality of care but also turning to an everlasting modification in human body and mind. Health policymakers and the academic community should begin investigating the current consumption of lifestyle medicines and its possible impacts, and develop regulatory policies accordingly.

1. (2006)。打擊偽藥藥廠出招。聯合報(2006/06/08)。
2. (1998).Go on, it`s good for you [Editorial].The Economist,348,51-52.
3. Ashworth M,Clement S,Wright M.(2002).Demand, appropriateness and prescribing of `lifestyle drugs`: a consultation survey in general practice.Fam Pract,19,236-241.
4. Atkinson T.(2002).Lifestyle drug market booming.Nat Med,8,909.
5. Bell RA,Kravitz RL,Wikes MS.(1999).Direct-to-consumer prescription drug advertising and the public.J Gen Intern Med,14,651-657.
6. Bostrom N.(2005).In defense of posthuman dignity.Bioethics,19,202-214.
7. Conrad P.(1975).The discovery of hyperkinesis: notes on the medicalization of deviant behavior.Soc Probl,23,12-21.
8. DeCamp M.(2002).Ethics and the physician-patient relationship: medico-moral consequences of commodification.Einstein J Biol Med,19,135-138.
9. Deckard GJ.(1995).Physician responses to a managed environment: a perceptual paradox.Health Care Manage Rev,20,40-46.
10. Elliott C.(2003).Better than Well: American Medicine Meets the American Dream.New York:W.W. Norton.
11. Emanuel L.(1997).Bringing market medicine to professional account.JAMA,277,1004-1005.
12. Flower R.(2004).Lifestyle drugs: pharmacology and the social agenda.Trends Pharmacol Sci,25,182-185.
13. Frankel S,Ebrahim S,Davey Smith G.(2000).The limits to demand for health care.BMJ,321,40-45.
14. Garg RK,Khaishgi A,Dandona P.(1999).Is management of impotence with sildenafil changing clinical practice?.Lancet,353,375-376.
15. Gilbert D.(1999).Lifestyle Drugs: Who Will Pay? Scrip Report.London:PJB.
16. Gilbert D,Walley T,New B.(2000).Lifestyle medicines.BMJ,321,1341-1344.
17. Haiken E.(1999).Venus Envy: A History of Cosmetic Surgery.Baltimore, MD:The Johns Hopkins University Press.
18. Hoffman JR,Wilkes M.(1999).Direct to consumer advertising of prescription drugs: an idea whose time should not come.BMJ,318,1301-1302.
19. Hogle LF.(2005).Enhancement technologies and the body.Annu Rev Anthropol,34,695-716.
20. Holmer AF.(1999).Direct-to-Consumer prescription drug advertising builds bridges between patients and physicians.JAMA,281,380-382.
21. Illich I.(1975).Medical Nemesis: The Expropriation of Health.New York:Pantheon Books.
22. Lifestyle drugs: potion for growth
23. Kapiriri L,Martin DK.(2007).Bedside rationing by health practitioners: a case study in a Ugandan hospital.Med Decis Making,27,44-52.
24. Klein R,Sturm H.(2002).Viagra: a success story for rationing?.Health Aff,21,177-187.
25. Lifestyle drugs: new avenues
26. Lexchin J.(2001).Lifestyle drugs: issues for debate.CMAJ,164,1449-1451.
27. Lexchin J.(2006).Bigger and better: how Pfizer redefined erectile dysfunction.PLoS Med,3,132.
28. Mackintosh M,Koivusalo M.(eds.)(2005).Commercialization of Health Care: Global and Local Dynamics and Policy Responses.Basingstoke:Palgrave Macmillan.
29. Mansfield PR,Mintzes B,Richards D.(2005).Direct to consumer advertising is at the crossroads of competing pressures from industry and health needs.BMJ,330,5-6.
30. Martin E.(2000).Mind-body problems.Amer Ethnologists,27,569-590.
31. McArthur JH,Moore FD.(1997).The two cultures and the health care revolution. Commerce and professionalism in medical care.JAMA,277,985-999.
32. Mehlman MJ.(2004).Cognition-enhancing drugs.Milbank Q,82,483-506.
33. Miller FG,Brody H.(2005).Enhancement technologies and professional integrity.Am J Bioethics,5,15-17.
34. Mintzes B,Barer ML,Kravitz RL(2003).How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA.CMAJ,169,405-412.
35. Mitrany D.(2001).Lifestyle drugs: determining their value and who should pay.Pharmacoeconomics,19(Parts 1 and 2),441-448.
36. Møldrup C.(2004).The use of the terms `lifestyle medicines` or `lifestyle drugs`.Pharm World Sci,26,193-196.
37. Moynihan R,Heath I,Henry D,Gotzsche PC.(2002).Selling sickness: the pharmaceutical industry and disease mongering. Commentary: medicalisation of risk factors.BMJ,324,886-891.
38. Moynihan R,Smith R.(2002).Too much medicine: almost certainly.BMJ,324,859-860.
39. Murray E,Lo B,Pollack L,Donelan K.(2003).Direct-to-consumer advertising: physicians` views of its effects on quality of care and the doctor-patient relationship.J Am Board Fam Pract,16,513-524.
40. Overman S.(1998).Warning: Viagra may cause headaches for health insurers.HR Magazine,43,104-109.
41. Parens E.(2005).Authenticity and ambivalence: toward understanding the enhancement debate.Hastings Cent Rep,35,34-41.
42. Lifestyle drugs
43. Phillips CB.(2006).Medicine goes to school: teachers as sickness brokers for ADHD.PLoS Med,3,182.
44. Relman AS.(1980).The new medical-industrial complex.N Engl J Med,303,963-970.
45. Relman AS.(1983).The future of medical practice.Health Aff,2,5-19.
46. Reuters Business Insight(2002).New Strategic Management Report.London:Reuters.
47. Rothman SM,Rothman D.(2003).The Pursuit of Perfection: The Promise and Perils of Medical Enhancement.New York:Pantheon Books.
48. Smith R.(2002).In search of "non-disease".BMJ,324,883-885.
49. The President`s Council on Bioethics(2003).Beyond Therapy: Biotechnology and the Pursuit of Happiness.New York:Regan Books.
50. Ubel PA,Goold S.(1997).Recognizing bedside rationing: clear cases and tough calls.Ann Intern Med,126,74-80.
51. Walley T.(2002).Lifestyle medicines and the elderly.Drugs Aging,19,163-168.
52. WHO(2006).Counterfeit medicines.WHO Drug Information,20,3-4.
53. Wick JY.(2002).Enhancing life or eradicating ugliness? Lifestyle drugs.J Manag Care Pharm,8,15-20.
54. Young SN.(2003).Lifestyle drugs, mood, behavior and cognition.J Psychiatry Neurosci,28,87-89.
55. 丁志音(1999)。醫師如何看待醫院的企業化經營管理趨勢？。中華衛誌，18，152-166。
56. 吳家勳(2005)。碩士論文(碩士論文)。桃園，元智大學管理研究所。
57. 宋奉宜(2003)。碩士論文(碩士論文)。桃園，長庚大學醫務管理研究所。
58. 李樹人(2006)。向錢衝！骨科、小兒科醫師學雷射。聯合報(2006/07/09)。
59. 胡宗鳳(2006)。生育率低婦科跨做美容醫學。聯合報(2006/09/27)。
60. 劉梅君、林志鴻(2006)。醫療階級化儼然成形，健保的公平正義遭侵蝕。聯合報民意論壇(2006/01/12)。

1. (2017)。藥品廣告規範之傳播政治經濟學取徑分析：跨領域議題規範新思維。傳播與社會學刊，42，189-223。